Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
IN-001 (L-dipivefrin) Sublingual Solution vs Epinephrine Injections in Healthy Adults
NCT07210320Phase 1Completed
- Sponsor
- Insignis Therapeutics
- Start
- Oct 2025
- Primary completion
- Apr 2026
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 1, randomised, open-label trial of dipivefrin in anaphylaxis and food allergy (4 arms), sponsored by Insignis Therapeutics. Primary endpoints: Maximum Observed Plasma Concentration and Time to Maximum Plasma Concentration. Started Oct 2025; status: completed.
02
Drugs
dipivefrin
03
Conditions
anaphylaxisfood allergy
Beyond the preview
Go deeper on NCT07210320.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT07210320.